It is now well established that G protein-coupled receptors can exist not only as homodimers, but also as heterodimers or higher order oligomers. However, whether and how dimerization of the receptors is regulated is poorly understood. In this issue of The EMBO Journal, the team of Marc Landry provides evidence for an intriguing mechanism by which-under pathological conditions-GABA B receptor heterodimers at the cell surface are disrupted and thereby inactivated. An impressive set of experiments thus reveals a novel mechanism regulating the number of functional GABA B receptors in the plasma membrane and shows that the receptor heterodimer may not be as stable as we previously thought.
It is evident that dimerization and oligomerization at least of class A and C G protein-coupled receptors (GPCRs) play important roles in permitting or enhancing their cell surface trafficking (Milligan, 2010) . The assembly process is thought to serve as a quality control mechanism to ensure that only fully mature and functional receptors reach the plasma membrane. The prototype of an obligatory heterodimer among GPCRs is the GABA B receptor, which controls excitability of neurons by mediating slow inhibitory neurotransmission (Gassmann and Bettler, 2012) . Functional GABA B receptors are built from two related proteins termed as GABA B1 and GABA B2 . Although both subunits display a similar structural organization-with a large extracellular domain containing a Venus fly-trap structure, seven transmembrane domains and a large intracellular located C-terminal domain-they serve distinct, complementary functions. GABA B1 binds the orthosteric ligands whereas GABA B2 recruits the G protein and is required for cell surface trafficking of the receptor complex by masking an ER Figure 1 Novel mechanism regulating GABA B receptor signalling by disrupting the functional receptor heterodimer via interaction with 14-3-3z. Functional GABA B receptors are obligatory heterodimers built from GABA B1 and GABA B2 subunits. Under normal conditions, binding of GABA to the Venus fly trap-like structure in the N-terminal domain of GABA B1 activates Gi/o proteins recruited by GABA B2 and thereby modulates distinct effector systems (adenylyl cyclases, potassium channels and voltage-gated Ca 2 þ channels). After induction of neuropathic pain by spinal nerve ligation, 14-3-3z is selectively upregulated in the spinal dorsal horn where painful sensory signals are processed and transmitted to the brain. 14-3-3z binds to the C-terminal domain of GABA B1 and disrupts by a yet-to-be identified mechanism the receptor dimer. This results in non-fuctional receptors and prevents GABA B receptor signalling. www.embojournal.org retention signal present in the C-terminal domain of GABA B1 . This is a striking example that dimerization is essential for and control of expression of a functional GPCR. The availability of GABA B receptors at the cell surface is also determined by receptor trafficking, which includes endocytosis, recycling and degradation of the receptors (Benke, 2010) . To maintain the required number of cell surface receptors for signalling under a given physiological status, all levels of receptor trafficking need to be precisely balanced. Changing the balance of the different trafficking mechanisms is one means to adjust receptor numbers to changing physiological conditions. An example of such regulation is the recently uncovered mechanism of the glutamate receptor-mediated downregulation of GABA B receptors where the balance of recycling and degradation of the receptors is shifted towards degradation . Laffray et al (2012) propose a novel and unexpected mechanism regulating the number of functional receptors at the cell surface. This mechanism is operative in vivo under pathological conditions and is based on the disruption of GABA B receptor heterodimers present in the plasma membrane by the GABA B1 interacting protein 14-3-3z.
Seven members of 14-3-3 proteins (14-3-3b, g, e, z, Z, s and t) are ubiquitously expressed in mammals. 14-3-3 proteins bind predominantly to phosphoserine and phosphothreonine containing sequences and interact with hundreds of different partners to regulate a variety of cellular processes ranging from protein trafficking, apoptosis, cell cycle, signal transduction, cell adhesion and metabolism. It is therefore not surprising that alterations in the expression levels of 14-3-3 proteins and/or changes in the interaction status with target proteins are increasingly observed in diseases such as cancer, neurodegenerative diseases and epilepsy (Zhao et al, 2011) . Among 14-3-3 proteins, 14-3-3z interacts with the C-terminal domain of GABA B1 and has been shown in vitro to inhibit the heterodimerization of GABA B1 and GABA B2 C-terminal domains (Couve et al, 2001 ). However, the physiological and potential pathological function of this interaction was entirely unresolved. In a rat model of neuropathic pain (spinal nerve ligation), Laffray et al (2012) observed a significant upregulation of 14-3-3z selectively in the ipsilateral dorsal horn of the lumbar spinal cord, the area where nociceptive signal processing in response to the injury takes place. Using several complementary methodologies including coimmunoprecipitation, colocalization immunofluorescence analysis, electron microscopy and two-photon fluorescence lifetime imaging, the authors demonstrated in vitro and in vivo that upregulation of 14-3-3z results in an increased interaction with GABA B1 in the plasma membrane and in a concomitant loss of GABA B1 /GABA B2 association. This finding suggests that 14-3-3z disrupts existing heterodimers in the plasma membrane ( Figure 1) . As a consequence, the increased GABA B1 /14-3-3z interaction rendered cell surface GABA B receptors non-functional and impaired GABA B receptor signalling.
The main unresolved and extremely interesting issue concerns the mechanism of heterodimer disruption by 14-3-3z. The interaction site of 14-3-3z partially overlaps with the coiled-coil domain in the C-terminal domain of GABA B1 (Couve et al, 2001 ). Coiled-coil domains are protein-protein interaction sites and are one of the domains thought to be involved in the heterodimerization of GABA B1 and GABA B2 . The most obvious mechanism is a direct competition of 14-3-3z and GABA B2 for interaction with GABA B1 . 14-3-3 proteins are inherently rigid proteins able to stabilize a given conformation after binding to its partner protein (Obsil and Obsilova, 2011) . Thus, binding of 14-3-3z might arrest GABA B1 in a conformation that is non-permissive for GABA B2 heterodimerization. However, the apparent affinity of the interaction of 14-3-3z with GABA B1 is rather low and relatively high concentrations of 14-3-3z are required to prevent heterodimerization of GABA B1 and GABA B2 C-terminal domains in vitro (Couve et al, 2001) . Given the relatively moderate increase of 14-3-3z in neuropathic spinal cord, a direct competition mechanism per se appears unlikely. On the other hand, 14-3-3 proteins predominantly bind to motifs containing phosphorserine and phosphothreonine. Therefore, phosphorylation of GABA B1 within the 14-3-3z binding site might thus foster the GABA B1 /14-3-3z interaction. In this regard, it would be important to test whether serine or threonine residues within the 14-3-3z binding site are phosphorylated in chronic pain states and whether phosphorylation is required for 14-3-3z interaction.
An alternative mechanism may be based on the scaffolding properties of 14-3-3 proteins. 14-3-3 proteins act as dimers and thus harbour at least two protein interaction sites (Obsil and Obsilova, 2011) . Therefore, 14-3-3z may target a second protein or a protein complex to GABA B receptors that forces the receptor complex to dissociate and prevent reassociation. Proteomic analyses of isolated GABA B1 /14-3-3z complexes are needed to address this issue.
Another important aspect of the paper is that it sheds some light on the involvement of GABA B receptors in neuropathic pain. So far, there is no coherent picture on the contribution of GABA B receptors to chronic pain states. However, there is increasing evidence that diminished GABA B receptor activity due to downregulation of the receptors might play a role in at least some models of neuropathic pain (Zeilhofer et al, 2012) . Although there might be distinct mechanisms downregulating functional GABA B receptors in chronic pain conditions, disruption of GABA B receptor heterodimers via upregulation of 14-3-3z appears to be a contributing factor. In their neuropathic pain model, Laffray et al (2012) observed a diminished analgesic activity of the intrathecally injected GABA B receptor agonist baclofen. Preventing the binding of 14-3-3z to GABA B receptors via knocking-down 14-3-3z with siRNA or by using a synthetic peptide disrupting the GABA B1 / 14-3-3 interaction restored expression of GABA B receptor heterodimers in the plasma membrane and consequently enhanced the analgesic effect of baclofen. Even more important, disruption of the 14-3-3z/GABA B1 interaction by injection of the interfering synthetic peptide alone in the absence of baclofen partially reversed pain in the neuropathic rats. This finding implies that diminished GABA B receptor signalling contributes to the expression of neuropathic pain. These results might be a starting point for a therapeutic strategy to reduce neuropathic pain based on reversing the GABA B1 /14-3-3z interaction. There are already small molecule inhibitors of 14-3-3 protein-protein interactions under development (Zhao et al, 2011) , which might be useful for testing the feasibility of such an approach.
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